Scarica l'app Stockscreener
27.92
3.68%
0.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$26.93
Aprire:
$27.65
Volume 24 ore:
1.83M
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.83B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-15.43
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+5.28%
1M Prestazione:
-19.19%
6M Prestazione:
+59.36%
1 anno Prestazione:
-2.41%
Intervallo 1D:
$27.33
$29.26
Intervallo di 1 settimana:
$25.23
$29.26
Portata 52W:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.92 | 2.73B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Wedbush Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Prime Editing and CRISPR Market Set for Explosive Growth at 24.1% - openPR.com
Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn
Beam Therapeutics Secures Standby License for Key Patents - TipRanks
Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (BEAM) - Stock Traders Daily
Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus
What’s the outlook for Beam Therapeutics Inc.’s sectorJuly 2025 Levels & Fast Gain Swing Trade Alerts - mfd.ru
Why Beam Therapeutics Inc. stock appeals to analystsTreasury Yields & Risk Managed Investment Strategies - mfd.ru
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside - DirectorsTalk Interviews
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics announces upcoming board member resignation - TipRanks
Director Carole Ho to leave Beam Therapeutics (NASDAQ: BEAM) board - Stock Titan
Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6%Here's Why - MarketBeat
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途资讯
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Beam soars 22% as FDA signs off on its ambitious gene-editing plan - MSN
Growth Report: Is Butterfly Network Inc Equity Warrant stock a buy or sellMarket Sentiment Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat
Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral
Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX), Beam Therapeutics (BEAM) and Boston Scientific (BSX) - The Globe and Mail
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus
Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):